Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Flat pricing of ibrutinib

Sales revenues at the potential expense of patient safety https://cancerletter.com/articles/20180413_5/

A group of oncologists is urging the Food and Drug Administration to review a new, flat-pricing strategy for all doses of ibrutinib (Imbruvica), calling the shift potentially dangerous for patients.

Pharmacyclics, an AbbVie company based in Sunnyvale, Calif., recently introduced a new, single-tablet formulation of ibrutinib in varying strengths (140 mg, 280 mg, 420 mg, and 560 mg) and set a flat price across all doses. At the same time, they removed the drug’s original 140-mg capsules – which cost about a third of the new, flat-rate price – from the market. The drug company says the new, single-tablet formulations give patients a convenient, once-a-day dosing regimen that could improve therapy adherence.

The new pricing system makes it harder for physicians to adjust the dose without running afoul of insurers and potentially affecting access for patients.

Read the article.

Citation:

Sales revenues at the potential expense of patient safety https://cancerletter.com/articles/20180413_5/

This Week's Must Reads

Overall survival factor in metastatic ccRCC, Thiery-Vuillemin A et al. Clinical Genitourinary Cancer 2018; 16: e297-e305

High perirenal fat thickness predicts poor progression-free survival in patients with localized ccRCC, Huang H et al. Urologic Oncology: Seminars and Original Investigations 2018; 36: 157.e1-157.e6

AXL linked to worse outcome of metastatic RCCs treated with sunitinib, Zucca L E et al. Urologic Oncology: Seminars and Original Investigations 2018: 36; 11.e13-11.e21

Pathologic predictors in lymph node dissection of metastatic RCC, Chipollini J et al. Clinical Genitourinary Cancer 2018; 16: Pages e443-450.

Plated-lymphocyte ratio is correlated with poor prognosis in RCC, Wang Z et al. Clinica Chimica Acta; 2018; 480: 166-72.

Must Reads in Practice Management

Flat pricing of ibrutinib , Sales revenues at the potential expense of patient safety https://cancerletter.com/articles/20180413_5/

Most oncologists discuss medical marijuana with patients, Braun I et al. J Clin Oncol. 2018 May 10. doi: 10.1200/JCO.2017.76.1221.

$800M cut proposed for Centers for Medicare & Medicaid Innovation, Proposed rescission of budget authority https://www.whitehouse.gov/wp-content/uploads/2018/05/POTUS-Rescission-Transmittal-Package-5.8.2018.pdf

Medicare Beneficiary Identifiers required for billing by 2019, New Medicare cards https://www.cms.gov/medicare/new-medicare-card/nmc-home.html

Trump administration unveils drug pricing initiative, American Patients First https://www.hhs.gov/sites/default/files/AmericanPatientsFirst.pdf